CY1112643T1 - Διενυδρη υδροχλωρικη ναλμεφαινη - Google Patents

Διενυδρη υδροχλωρικη ναλμεφαινη

Info

Publication number
CY1112643T1
CY1112643T1 CY20121100278T CY121100278T CY1112643T1 CY 1112643 T1 CY1112643 T1 CY 1112643T1 CY 20121100278 T CY20121100278 T CY 20121100278T CY 121100278 T CY121100278 T CY 121100278T CY 1112643 T1 CY1112643 T1 CY 1112643T1
Authority
CY
Cyprus
Prior art keywords
nalmefein
hydrochlorine
hydrochloric
nalmefine
hydrochloride dihydrate
Prior art date
Application number
CY20121100278T
Other languages
English (en)
Inventor
De Diego Heidi Lopez
Faveri Carla De
Florian Anton Martin Huber
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41571731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112643(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1112643T1 publication Critical patent/CY1112643T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε διένυδρη υδροχλωρική Ναλμεφαίνη, μεθόδους βιομηχανικής κατασκευής διενύδρου υδροχλωρικής Ναλμεφαίνης, φαρμακευτική σύνθεση που περιλαμβάνει διένυδρη υδροχλωρική Ναλμεφαίνη και μέθοδο θεραπείας που περιλαμβάνει χορήγηση διενύδρου υδροχλωρικής Ναλμεφαίνης.
CY20121100278T 2008-12-05 2012-03-15 Διενυδρη υδροχλωρικη ναλμεφαινη CY1112643T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12013208P 2008-12-05 2008-12-05
DKPA200801729 2008-12-05
EP09771286A EP2300479B1 (en) 2008-12-05 2009-12-04 Nalmefene hydrochloride dihydrate

Publications (1)

Publication Number Publication Date
CY1112643T1 true CY1112643T1 (el) 2016-02-10

Family

ID=41571731

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100278T CY1112643T1 (el) 2008-12-05 2012-03-15 Διενυδρη υδροχλωρικη ναλμεφαινη
CY20141100563T CY1115381T1 (el) 2008-12-05 2014-07-25 Διενυδρη υδροχλωρικη ναλμεφαινη

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20141100563T CY1115381T1 (el) 2008-12-05 2014-07-25 Διενυδρη υδροχλωρικη ναλμεφαινη

Country Status (31)

Country Link
US (2) US8530495B2 (el)
EP (2) EP2300479B1 (el)
JP (3) JP6055183B2 (el)
KR (2) KR20170008893A (el)
CN (2) CN102325778B (el)
AR (1) AR074507A1 (el)
AT (1) ATE546453T1 (el)
AU (1) AU2009321898B2 (el)
BR (1) BRPI0922774B8 (el)
CA (1) CA2744932C (el)
CL (1) CL2011001331A1 (el)
CO (1) CO6362012A2 (el)
CY (2) CY1112643T1 (el)
DK (2) DK2441766T3 (el)
EA (1) EA018948B1 (el)
ES (2) ES2488165T3 (el)
HK (1) HK1205108A1 (el)
HR (2) HRP20120247T1 (el)
IL (1) IL213112A (el)
MX (1) MX2011005865A (el)
MY (1) MY149028A (el)
NZ (1) NZ593874A (el)
PL (2) PL2441766T3 (el)
PT (2) PT2441766E (el)
RS (2) RS52255B (el)
SG (1) SG171910A1 (el)
SI (2) SI2300479T1 (el)
SM (2) SMT201200014B (el)
TW (1) TWI465450B (el)
UA (1) UA102128C2 (el)
WO (1) WO2010063292A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
JP2019031524A (ja) * 2008-12-05 2019-02-28 ハー・ルンドベック・アクチエゼルスカベット ナルメフェン塩酸塩二水和物
TWI560170B (en) * 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
US20140155608A1 (en) 2012-05-03 2014-06-05 H. Lundbeck A/S Method for the manufacturing of naltrexone
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
JP6419780B2 (ja) * 2013-04-17 2018-11-07 ハー・ルンドベック・アクチエゼルスカベット 睡眠障害患者の治療のためのナルメフェン
US20160058754A1 (en) * 2013-04-17 2016-03-03 H. Lundbeck A/S Nalmefene for Treatment of Patients with Anxiety Disorder
AR096851A1 (es) * 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
ES2742888T3 (es) 2014-04-22 2020-02-17 Otsuka Pharma Co Ltd Combinación de brexpiprazol y nalmefeno y su uso para tratar trastornos relacionados con una sustancia
TWI729644B (zh) 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN105646508B (zh) * 2016-02-17 2018-02-27 南京卓康医药科技有限公司 一种盐酸纳美芬一水合物的制备方法
WO2019022274A1 (ko) * 2017-07-28 2019-01-31 동아대학교 산학협력단 Pauf 단백질에 특이적으로 결합하는 항체 및 이의 용도
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
CN111875530A (zh) * 2020-08-17 2020-11-03 浙江朗华制药有限公司 一种普拉西坦水合物晶体及其制备方法
WO2022165040A1 (en) 2021-01-28 2022-08-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN113354652A (zh) * 2021-06-24 2021-09-07 无锡济煜山禾药业股份有限公司 一种盐酸纳美芬合成方法
CN117986261B (zh) * 2024-04-02 2024-06-18 成都瑞尔医药科技有限公司 一种盐酸纳美芬母液的回收套用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
CH693586A8 (de) * 2002-10-14 2003-12-15 Roche Consumer Health Ag Darreichungsform von Ibuprofen-Natrium.
FR2861299B1 (fr) * 2003-10-28 2006-01-27 Pf Medicament Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes
DK1708690T3 (en) * 2003-11-17 2016-11-07 Biomarin Pharm Inc TREATMENT OF PHENYLKETONURI WITH BH4
MY139797A (en) * 2004-11-29 2009-10-30 Kowa Co (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1, 4-homopiperazine hydrochloride dihydrate
CN100536848C (zh) * 2005-07-13 2009-09-09 北京易明康元医药科技有限公司 稳定的盐酸纳美芬注射液及其制备方法
GB2447013A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
GB2447016A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
CA2707757C (en) 2007-03-06 2017-01-03 Peter X. Wang Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
US8399475B2 (en) * 2007-04-12 2013-03-19 Mallinckrodt Llc Crystalline and amorphous forms of naltrexone hydrochloride
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate

Also Published As

Publication number Publication date
PL2300479T3 (pl) 2012-06-29
JP2012510954A (ja) 2012-05-17
AU2009321898B2 (en) 2014-10-02
JP6591759B2 (ja) 2019-10-16
JP6055183B2 (ja) 2016-12-27
JP2017025079A (ja) 2017-02-02
TW201022273A (en) 2010-06-16
IL213112A0 (en) 2011-07-31
TWI465450B (zh) 2014-12-21
RS52255B (en) 2012-10-31
BRPI0922774A2 (pt) 2017-07-11
EA018948B1 (ru) 2013-11-29
EP2300479B1 (en) 2012-02-22
CN102325778B (zh) 2014-08-13
HK1205108A1 (en) 2015-12-11
BRPI0922774B8 (pt) 2021-05-25
US8754217B2 (en) 2014-06-17
MX2011005865A (es) 2011-09-06
US20130338365A1 (en) 2013-12-19
CA2744932A1 (en) 2010-06-10
EP2300479A1 (en) 2011-03-30
BRPI0922774B1 (pt) 2020-10-13
CY1115381T1 (el) 2017-01-04
UA102128C2 (en) 2013-06-10
SI2441766T1 (sl) 2014-12-31
US8530495B2 (en) 2013-09-10
CN104211707B (zh) 2017-04-12
RS53415B (en) 2014-12-31
ES2488165T3 (es) 2014-08-26
SI2300479T1 (sl) 2012-07-31
AR074507A1 (es) 2011-01-19
MY149028A (en) 2013-06-28
KR20170008893A (ko) 2017-01-24
EP2441766B1 (en) 2014-06-25
JP6591944B2 (ja) 2019-10-16
CL2011001331A1 (es) 2011-08-26
IL213112A (en) 2013-06-27
DK2441766T3 (da) 2014-07-21
SG171910A1 (en) 2011-07-28
KR20110089333A (ko) 2011-08-05
HRP20120247T1 (hr) 2012-05-31
ES2380297T3 (es) 2012-05-10
PT2441766E (pt) 2014-08-05
AU2009321898A1 (en) 2011-07-14
CN102325778A (zh) 2012-01-18
SMT201400113B (it) 2014-11-10
SMT201200014B (it) 2012-07-10
CO6362012A2 (es) 2012-01-20
ATE546453T1 (de) 2012-03-15
NZ593874A (en) 2013-02-22
US20110251228A1 (en) 2011-10-13
WO2010063292A1 (en) 2010-06-10
HRP20140648T1 (hr) 2014-09-26
EP2441766A1 (en) 2012-04-18
JP2015134785A (ja) 2015-07-27
DK2300479T3 (da) 2012-03-26
PL2441766T3 (pl) 2014-09-30
CA2744932C (en) 2013-05-07
CN104211707A (zh) 2014-12-17
PT2300479E (pt) 2012-04-10
EA201170753A1 (ru) 2011-12-30

Similar Documents

Publication Publication Date Title
CY1115381T1 (el) Διενυδρη υδροχλωρικη ναλμεφαινη
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1122366T1 (el) Θεραπεια της οξειας λεμφοβλαστικης λευχαιμιας
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
CY1122428T1 (el) Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19
CY1113220T1 (el) Απαραβιαστες φαρμακοτεχνικες μορφες δοσολογιας απο του στοματος περιλαμβανουσες ενα οπιουχο αναλγητικο
CY1119048T1 (el) Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CY1116064T1 (el) Συστασεις αναστολεα ddp iv
CY1115254T1 (el) Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις
CY1112558T1 (el) Ενωσεις ν-μεθυλαμινομεθυλο ισοϊνδολης και συνθεσεις που τις περιλαμβανουν και μεθοδοι χρησης τους
CY1113024T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων
CY1112813T1 (el) 4-(4-κυανο-2-θειοαρυλ)διϋδροπυριμιδινονες και η χρηση αυτων
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
CY1115081T1 (el) Νεο εκχυλισμα απο γαϊδουραγκαθο, μεθοδος για την παρασκευη και η χρηση του
CY1114190T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
CY1113551T1 (el) Υποκατεστημενες ενωσεις νικοτιναμιδιου και η χρησιμοποιηση τους σε φαρμακα
CY1118585T1 (el) Ενωση βενζοθειαζολονης
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
CY1123438T1 (el) Διαδικασια για παραγωγη και καθαρισμοανασυνδυασμενης λυσοσωμικης αλφα-μαννοσιδασης
CY1113641T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει aleglitazar
EA200970816A1 (ru) Новая лекарственная форма